Review Article
Liver Transplantation and Hepatitis C
Table 1
Factors associated with the severity of recurrent hepatitis C after liver transplantation.
| Variables | Effect on recurrent hepatitis C |
| Donor and graft factors | | Age | More severe disease (>40, >50, >65) | Steatosis | Few studies | Prolonged ischemic time | More severe disease | HCV+ graft | No influence | Reduced size versus whole liver (LDLT versus DDLT) | No difference | Pretransplant recipient factors | | Genotype 1b | Controversial | Pre-LT higher viral load | Unclear | Age | Few studies | Race | Few studies | Sex | Few studies | HIV coinfection | No influence | IL-28B gene polymorphism | More severe disease in CT and TT genotype | Posttransplant recipient factors | | Post-LT higher viral load | More severe disease | CMV infection | Unclear More severe disease | Diabetes mellitus (metabolic syndrome) | More severe disease | Immunosuppression | | Steroid bolus | More severe disease | OKT3 | More severe disease | Maintenance steroid | Severe disease when rapidly tapered | Steroid free regimen | No influence | Tacrolimus versus Cyclosporine | No difference | Anti-IL-2 receptor antibodies | Controversial | Azathioprine | Controversial | Mycophenolate mofetil | Controversial | mTOR inhibitors | Few studies |
|
|
Abbreviations: CMV: cytomegalovirus; DDLT: deceased donor liver transplantation; HCV: hepatitis C virus; HIV: human immunodeficiency virus; LDLT: living-donor liver transplantation; LT: liver transplantation; mTOR: mammalian target of rapamycin.
|